1[1]Van Dullemen HM,Van Deventer SJ,Hommes DW,et al.Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)[J].Gastroenterology,1995,109(1)∶129-135．
2[2]McCade RP,Woody J,Van Deventer SJ,et al.A multi-center trial of cA2 anti-TNF-α chimeric monoclonal antibody in patients with active Crohn's desease[J].Gastroenterology，1996,110(Suppl 4)∶A962．
3[3]Targan SR,Hanauer SB,Van Deventer SJ,et al.A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor in Crohn's disease[J].N Engl J Med，1997,337（15）∶1029-1035．
4[4]Program and abstracts of Digestive Disease Week[C].May 21-24, 2000.San Diego, California. Abstract 2958-2976,3051,3595,3596,4848．
5[5]Lichtenstein GR,Stein R,Lewis JD,et al.The presence of intestinal structures is associated with poorer responses for active or fistulizing Crohn's disease[J].Am J Gastroenterol，1999，94（9）∶2676．
6[6]Program and abstracts from the 64th Annual Scientific meeting of the American college of Rheumatology[C].October 29-November 2,2000.Philadelphia,Pennsylvania.Abstract 606.
